Envestnet Asset Management
HRTX icon

Envestnet Asset Management’s Heron Therapeutics HRTX Stock Holding History

Envestnet Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,591
Closed -$10.9K – 4886
2026
Q1 		$10.9K Buy
+13,591
New +$15.7K ﹤0.01% 4697
2025
Q4 		– Sell
-14,780
Closed -$18.6K – 4548
2025
Q3 		$18.6K Sell
14,780
-3,684
-20% -$5.84K ﹤0.01% 4495
2025
Q2 		$38.2K Sell
18,464
-466
-2% -$952 ﹤0.01% 4395
2025
Q1 		$41.6K Buy
18,930
+1,182
+7% +$2.29K ﹤0.01% 4302
2024
Q4 		$27.2K Sell
17,748
-10,092
-36% -$16.4K ﹤0.01% 4280
2024
Q3 		$55.4K Buy
27,840
+8,683
+45% +$20.7K ﹤0.01% 4173
2024
Q2 		$67K Buy
19,157
+1,158
+6% +$3.56K ﹤0.01% 4088
2024
Q1 		$49.9K Buy
17,999
+4,576
+34% +$11.5K ﹤0.01% 4108
2023
Q4 		$22.8K Buy
13,423
+3,291
+32% +$3.62K ﹤0.01% 4017
2023
Q3 		$10.4K Buy
+10,132
New +$14.4K ﹤0.01% 3994
2022
Q1 		– Sell
-11,796
Closed -$108K – 3990
2021
Q4 		$108K Buy
+11,796
New +$120K ﹤0.01% 3756
2020
Q1 		– Sell
-55,406
Closed -$1.3M – 3045
2019
Q4 		$1.3M Buy
55,406
+2,427
+5% +$53.7K ﹤0.01% 1859
2019
Q3 		$980K Buy
52,979
+4,247
+9% +$78.2K ﹤0.01% 1957
2019
Q2 		$906K Sell
48,732
-2,200
-4% -$43.9K ﹤0.01% 2013
2019
Q1 		$1.25M Buy
50,932
+6,047
+13% +$158K ﹤0.01% 1753
2018
Q4 		$1.16M Buy
+44,885
New +$1.23M ﹤0.01% 1639
2018
Q3 		– Sell
-1,337
Closed -$52K – 1856
2018
Q2 		$52K Sell
1,337
-2
-0.1% -$64 ﹤0.01% 2197
2018
Q1 		$37K Buy
+1,339
New +$30.4K ﹤0.01% 2227

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Envestnet Asset Management's HRTX Position: Q2 2026 in Review

Envestnet Asset Management sold out of Heron Therapeutics (HRTX) in Q2 2026, closing a stake of 13,591 shares — an estimated $10.9K sold.

Envestnet Asset Management first reported a position in HRTX in Q1 2018 and held it in 18 quarters. The position peaked at $1.3M in Q4 2019. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Envestnet Asset Management reported no remaining Heron Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Envestnet Asset Management sold 13,591 Heron Therapeutics shares in Q2 2026, an estimated $10.9K.
  • Envestnet Asset Management first reported a position in Heron Therapeutics in Q1 2018 and held it in 18 quarters.
  • Envestnet Asset Management's Heron Therapeutics position peaked at $1.3M in Q4 2019.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.